Copyright Reports & Markets. All rights reserved.

Global Melanoma Skin Cancer Diagnostic Testing Market Size, Status and Forecast 2021-2027

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Market Analysis by Type
    • 1.2.1 Global Melanoma Skin Cancer Diagnostic Testing Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
    • 1.2.2 Biopsy
    • 1.2.3 Imaging
    • 1.2.4 Others
  • 1.3 Market by Application
    • 1.3.1 Global Melanoma Skin Cancer Diagnostic Testing Market Share by Application: 2016 VS 2021 VS 2027
    • 1.3.2 Hospitals
    • 1.3.3 Dermatology Clinics
    • 1.3.4 Diagnostic Laboratories
    • 1.3.5 Others
  • 1.4 Study Objectives
  • 1.5 Years Considered

2 Global Growth Trends

  • 2.1 Global Melanoma Skin Cancer Diagnostic Testing Market Perspective (2016-2027)
  • 2.2 Melanoma Skin Cancer Diagnostic Testing Growth Trends by Regions
    • 2.2.1 Melanoma Skin Cancer Diagnostic Testing Market Size by Regions: 2016 VS 2021 VS 2027
    • 2.2.2 Melanoma Skin Cancer Diagnostic Testing Historic Market Share by Regions (2016-2021)
    • 2.2.3 Melanoma Skin Cancer Diagnostic Testing Forecasted Market Size by Regions (2022-2027)
  • 2.3 Melanoma Skin Cancer Diagnostic Testing Industry Dynamic
    • 2.3.1 Melanoma Skin Cancer Diagnostic Testing Market Trends
    • 2.3.2 Melanoma Skin Cancer Diagnostic Testing Market Drivers
    • 2.3.3 Melanoma Skin Cancer Diagnostic Testing Market Challenges
    • 2.3.4 Melanoma Skin Cancer Diagnostic Testing Market Restraints

3 Competition Landscape by Key Players

  • 3.1 Global Top Melanoma Skin Cancer Diagnostic Testing Players by Revenue
    • 3.1.1 Global Top Melanoma Skin Cancer Diagnostic Testing Players by Revenue (2016-2021)
    • 3.1.2 Global Melanoma Skin Cancer Diagnostic Testing Revenue Market Share by Players (2016-2021)
  • 3.2 Global Melanoma Skin Cancer Diagnostic Testing Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.3 Players Covered: Ranking by Melanoma Skin Cancer Diagnostic Testing Revenue
  • 3.4 Global Melanoma Skin Cancer Diagnostic Testing Market Concentration Ratio
    • 3.4.1 Global Melanoma Skin Cancer Diagnostic Testing Market Concentration Ratio (CR5 and HHI)
    • 3.4.2 Global Top 10 and Top 5 Companies by Melanoma Skin Cancer Diagnostic Testing Revenue in 2020
  • 3.5 Melanoma Skin Cancer Diagnostic Testing Key Players Head office and Area Served
  • 3.6 Key Players Melanoma Skin Cancer Diagnostic Testing Product Solution and Service
  • 3.7 Date of Enter into Melanoma Skin Cancer Diagnostic Testing Market
  • 3.8 Mergers & Acquisitions, Expansion Plans

4 Melanoma Skin Cancer Diagnostic Testing Breakdown Data by Type

  • 4.1 Global Melanoma Skin Cancer Diagnostic Testing Historic Market Size by Type (2016-2021)
  • 4.2 Global Melanoma Skin Cancer Diagnostic Testing Forecasted Market Size by Type (2022-2027)

5 Melanoma Skin Cancer Diagnostic Testing Breakdown Data by Application

  • 5.1 Global Melanoma Skin Cancer Diagnostic Testing Historic Market Size by Application (2016-2021)
  • 5.2 Global Melanoma Skin Cancer Diagnostic Testing Forecasted Market Size by Application (2022-2027)

6 North America

  • 6.1 North America Melanoma Skin Cancer Diagnostic Testing Market Size (2016-2027)
  • 6.2 North America Melanoma Skin Cancer Diagnostic Testing Market Size by Type
    • 6.2.1 North America Melanoma Skin Cancer Diagnostic Testing Market Size by Type (2016-2021)
    • 6.2.2 North America Melanoma Skin Cancer Diagnostic Testing Market Size by Type (2022-2027)
    • 6.2.3 North America Melanoma Skin Cancer Diagnostic Testing Market Size by Type (2016-2027)
  • 6.3 North America Melanoma Skin Cancer Diagnostic Testing Market Size by Application
    • 6.3.1 North America Melanoma Skin Cancer Diagnostic Testing Market Size by Application (2016-2021)
    • 6.3.2 North America Melanoma Skin Cancer Diagnostic Testing Market Size by Application (2022-2027)
    • 6.3.3 North America Melanoma Skin Cancer Diagnostic Testing Market Size by Application (2016-2027)
  • 6.4 North America Melanoma Skin Cancer Diagnostic Testing Market Size by Country
    • 6.4.1 North America Melanoma Skin Cancer Diagnostic Testing Market Size by Country (2016-2021)
    • 6.4.2 North America Melanoma Skin Cancer Diagnostic Testing Market Size by Country (2022-2027)
    • 6.4.3 United States
    • 6.4.4 Canada

7 Europe

  • 7.1 Europe Melanoma Skin Cancer Diagnostic Testing Market Size (2016-2027)
  • 7.2 Europe Melanoma Skin Cancer Diagnostic Testing Market Size by Type
    • 7.2.1 Europe Melanoma Skin Cancer Diagnostic Testing Market Size by Type (2016-2021)
    • 7.2.2 Europe Melanoma Skin Cancer Diagnostic Testing Market Size by Type (2022-2027)
    • 7.2.3 Europe Melanoma Skin Cancer Diagnostic Testing Market Size by Type (2016-2027)
  • 7.3 Europe Melanoma Skin Cancer Diagnostic Testing Market Size by Application
    • 7.3.1 Europe Melanoma Skin Cancer Diagnostic Testing Market Size by Application (2016-2021)
    • 7.3.2 Europe Melanoma Skin Cancer Diagnostic Testing Market Size by Application (2022-2027)
    • 7.3.3 Europe Melanoma Skin Cancer Diagnostic Testing Market Size by Application (2016-2027)
  • 7.4 Europe Melanoma Skin Cancer Diagnostic Testing Market Size by Country
    • 7.4.1 Europe Melanoma Skin Cancer Diagnostic Testing Market Size by Country (2016-2021)
    • 7.4.2 Europe Melanoma Skin Cancer Diagnostic Testing Market Size by Country (2022-2027)
    • 7.4.3 Germany
    • 7.4.4 France
    • 7.4.5 U.K.
    • 7.4.6 Italy
    • 7.4.7 Russia
    • 7.4.8 Nordic

8 Asia-Pacific

  • 8.1 Asia-Pacific Melanoma Skin Cancer Diagnostic Testing Market Size (2016-2027)
  • 8.2 Asia-Pacific Melanoma Skin Cancer Diagnostic Testing Market Size by Type
    • 8.2.1 Asia-Pacific Melanoma Skin Cancer Diagnostic Testing Market Size by Type (2016-2021)
    • 8.2.2 Asia-Pacific Melanoma Skin Cancer Diagnostic Testing Market Size by Type (2022-2027)
    • 8.2.3 Asia-Pacific Melanoma Skin Cancer Diagnostic Testing Market Size by Type (2016-2027)
  • 8.3 Asia-Pacific Melanoma Skin Cancer Diagnostic Testing Market Size by Application
    • 8.3.1 Asia-Pacific Melanoma Skin Cancer Diagnostic Testing Market Size by Application (2016-2021)
    • 8.3.2 Asia-Pacific Melanoma Skin Cancer Diagnostic Testing Market Size by Application (2022-2027)
    • 8.3.3 Asia-Pacific Melanoma Skin Cancer Diagnostic Testing Market Size by Application (2016-2027)
  • 8.4 Asia-Pacific Melanoma Skin Cancer Diagnostic Testing Market Size by Region
    • 8.4.1 Asia-Pacific Melanoma Skin Cancer Diagnostic Testing Market Size by Region (2016-2021)
    • 8.4.2 Asia-Pacific Melanoma Skin Cancer Diagnostic Testing Market Size by Region (2022-2027)
    • 8.4.3 China
    • 8.4.4 Japan
    • 8.4.5 South Korea
    • 8.4.6 Southeast Asia
    • 8.4.7 India
    • 8.4.8 Australia

9 Latin America

  • 9.1 Latin America Melanoma Skin Cancer Diagnostic Testing Market Size (2016-2027)
  • 9.2 Latin America Melanoma Skin Cancer Diagnostic Testing Market Size by Type
    • 9.2.1 Latin America Melanoma Skin Cancer Diagnostic Testing Market Size by Type (2016-2021)
    • 9.2.2 Latin America Melanoma Skin Cancer Diagnostic Testing Market Size by Type (2022-2027)
    • 9.2.3 Latin America Melanoma Skin Cancer Diagnostic Testing Market Size by Type (2016-2027)
  • 9.3 Latin America Melanoma Skin Cancer Diagnostic Testing Market Size by Application
    • 9.3.1 Latin America Melanoma Skin Cancer Diagnostic Testing Market Size by Application (2016-2021)
    • 9.3.2 Latin America Melanoma Skin Cancer Diagnostic Testing Market Size by Application (2022-2027)
    • 9.3.3 Latin America Melanoma Skin Cancer Diagnostic Testing Market Size by Application (2016-2027)
  • 9.4 Latin America Melanoma Skin Cancer Diagnostic Testing Market Size by Country
    • 9.4.1 Latin America Melanoma Skin Cancer Diagnostic Testing Market Size by Country (2016-2021)
    • 9.4.2 Latin America Melanoma Skin Cancer Diagnostic Testing Market Size by Country (2022-2027)
    • 9.4.3 Mexico
    • 9.4.4 Brazil

10 Middle East & Africa

  • 10.1 Middle East & Africa Melanoma Skin Cancer Diagnostic Testing Market Size (2016-2027)
  • 10.2 Middle East & Africa Melanoma Skin Cancer Diagnostic Testing Market Size by Type
    • 10.2.1 Middle East & Africa Melanoma Skin Cancer Diagnostic Testing Market Size by Type (2016-2021)
    • 10.2.2 Middle East & Africa Melanoma Skin Cancer Diagnostic Testing Market Size by Type (2022-2027)
    • 10.2.3 Middle East & Africa Melanoma Skin Cancer Diagnostic Testing Market Size by Type (2016-2027)
  • 10.3 Middle East & Africa Melanoma Skin Cancer Diagnostic Testing Market Size by Application
    • 10.3.1 Middle East & Africa Melanoma Skin Cancer Diagnostic Testing Market Size by Application (2016-2021)
    • 10.3.2 Middle East & Africa Melanoma Skin Cancer Diagnostic Testing Market Size by Application (2022-2027)
    • 10.3.3 Middle East & Africa Melanoma Skin Cancer Diagnostic Testing Market Size by Application (2016-2027)
  • 10.4 Middle East & Africa Melanoma Skin Cancer Diagnostic Testing Market Size by Country
    • 10.4.1 Middle East & Africa Melanoma Skin Cancer Diagnostic Testing Market Size by Country (2016-2021)
    • 10.4.2 Middle East & Africa Melanoma Skin Cancer Diagnostic Testing Market Size by Country (2022-2027)
    • 10.4.3 Turkey
    • 10.4.4 Saudi Arabia
    • 10.4.5 UAE

11 Key Players Profiles

  • 11.1 Myriad Genetics
    • 11.1.1 Myriad Genetics Company Details
    • 11.1.2 Myriad Genetics Business Overview
    • 11.1.3 Myriad Genetics Melanoma Skin Cancer Diagnostic Testing Introduction
    • 11.1.4 Myriad Genetics Revenue in Melanoma Skin Cancer Diagnostic Testing Business (2016-2021)
    • 11.1.5 Myriad Genetics Recent Development
  • 11.2 Abbott Laboratories
    • 11.2.1 Abbott Laboratories Company Details
    • 11.2.2 Abbott Laboratories Business Overview
    • 11.2.3 Abbott Laboratories Melanoma Skin Cancer Diagnostic Testing Introduction
    • 11.2.4 Abbott Laboratories Revenue in Melanoma Skin Cancer Diagnostic Testing Business (2016-2021)
    • 11.2.5 Abbott Laboratories Recent Development
  • 11.3 Foundation Medicine
    • 11.3.1 Foundation Medicine Company Details
    • 11.3.2 Foundation Medicine Business Overview
    • 11.3.3 Foundation Medicine Melanoma Skin Cancer Diagnostic Testing Introduction
    • 11.3.4 Foundation Medicine Revenue in Melanoma Skin Cancer Diagnostic Testing Business (2016-2021)
    • 11.3.5 Foundation Medicine Recent Development
  • 11.4 Pathway Genomics Corporation
    • 11.4.1 Pathway Genomics Corporation Company Details
    • 11.4.2 Pathway Genomics Corporation Business Overview
    • 11.4.3 Pathway Genomics Corporation Melanoma Skin Cancer Diagnostic Testing Introduction
    • 11.4.4 Pathway Genomics Corporation Revenue in Melanoma Skin Cancer Diagnostic Testing Business (2016-2021)
    • 11.4.5 Pathway Genomics Corporation Recent Development
  • 11.5 Cancer Genetics
    • 11.5.1 Cancer Genetics Company Details
    • 11.5.2 Cancer Genetics Business Overview
    • 11.5.3 Cancer Genetics Melanoma Skin Cancer Diagnostic Testing Introduction
    • 11.5.4 Cancer Genetics Revenue in Melanoma Skin Cancer Diagnostic Testing Business (2016-2021)
    • 11.5.5 Cancer Genetics Recent Development
  • 11.6 Castle Biosciences
    • 11.6.1 Castle Biosciences Company Details
    • 11.6.2 Castle Biosciences Business Overview
    • 11.6.3 Castle Biosciences Melanoma Skin Cancer Diagnostic Testing Introduction
    • 11.6.4 Castle Biosciences Revenue in Melanoma Skin Cancer Diagnostic Testing Business (2016-2021)
    • 11.6.5 Castle Biosciences Recent Development
  • 11.7 NeoGenomics
    • 11.7.1 NeoGenomics Company Details
    • 11.7.2 NeoGenomics Business Overview
    • 11.7.3 NeoGenomics Melanoma Skin Cancer Diagnostic Testing Introduction
    • 11.7.4 NeoGenomics Revenue in Melanoma Skin Cancer Diagnostic Testing Business (2016-2021)
    • 11.7.5 NeoGenomics Recent Development
  • 11.8 Dermtech
    • 11.8.1 Dermtech Company Details
    • 11.8.2 Dermtech Business Overview
    • 11.8.3 Dermtech Melanoma Skin Cancer Diagnostic Testing Introduction
    • 11.8.4 Dermtech Revenue in Melanoma Skin Cancer Diagnostic Testing Business (2016-2021)
    • 11.8.5 Dermtech Recent Development
  • 11.9 Sysmex Inostics
    • 11.9.1 Sysmex Inostics Company Details
    • 11.9.2 Sysmex Inostics Business Overview
    • 11.9.3 Sysmex Inostics Melanoma Skin Cancer Diagnostic Testing Introduction
    • 11.9.4 Sysmex Inostics Revenue in Melanoma Skin Cancer Diagnostic Testing Business (2016-2021)
    • 11.9.5 Sysmex Inostics Recent Development

12 Analyst's Viewpoints/Conclusions

    13 Appendix

    • 13.1 Research Methodology
      • 13.1.1 Methodology/Research Approach
      • 13.1.2 Data Source
    • 13.2 Disclaimer

    Global Melanoma Skin Cancer Diagnostic Testing Scope and Market Size
    Melanoma Skin Cancer Diagnostic Testing market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Melanoma Skin Cancer Diagnostic Testing market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

    Segment by Type
    Biopsy
    Imaging
    Others

    Segment by Application
    Hospitals
    Dermatology Clinics
    Diagnostic Laboratories
    Others

    By Region
    North America
    United States
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Nordic
    Rest of Europe
    Asia-Pacific
    China
    Japan
    South Korea
    Southeast Asia
    India
    Australia
    Rest of Asia
    Latin America
    Mexico
    Brazil
    Rest of Latin America
    Middle East & Africa
    Turkey
    Saudi Arabia
    UAE
    Rest of MEA

    By Company
    Myriad Genetics
    Abbott Laboratories
    Foundation Medicine
    Pathway Genomics Corporation
    Cancer Genetics
    Castle Biosciences
    NeoGenomics
    Dermtech
    Sysmex Inostics

    Buy now